News

Neoadjuvant nivolumab yielded a 68.2% clinical complete response rate in patients with resectable mismatch repair–deficient endometrial cancer.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Jonathan Trent, MD, discusses how proactive AE management, dose individualization, and liquid TKI formulations could improve treatment adherence and outcomes in GIST.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

The CDK4/6 inhibitor and aromatase inhibitor combination produced a 32% ORR and 48% clinical benefit rate at 6 months.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

Despite a higher response rate with the combination, the phase 2 MIROVA/AGO-OVAR 2.34 trial did not meet its primary PFS end point over chemotherapy.

Updated data from the phase 2 COLIBRI-1 trial suggest that immune microenvironment status at baseline and following ICB induction may predict long-term survival.

The FDA has accepted a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Lung cancer experts convened at an OncLive® Scientific Interchange and Workshop to discuss treatment sequencing in HER2+ NSCLC.

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.

The B7-H4–targeted antibody-drug conjugate produced confirmed response rates of 62% in PROC and 67% in endometrial cancer at the doses selected for phase 3 development.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Bulumtatug fuvedotin produced a confirmed ORR of 32.08% and a DCR of 81.13% in recurrent or metastatic cervical cancer, with no treatment-related deaths.

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

External validation of a circulating immune protein signature model confirmed its prognostic value for OS in recurrent ovarian cancer.

To figure out how to beat persister tumor cells, researchers at UCSF built a robotic system that treats thousands of mini tumors at once in the laboratory.

Experts in lung cancer gathered at an OncLive® Scientific Interchange and Workshop during the 2026 ASCO Annual Meeting to discuss HER2-mutated NSCLC.

Iza-bren improved PFS, OS, and response rates vs chemotherapy in pretreated metastatic TNBC, indicating a potential new standard of care.

Everett Meyer, MD, PhD, outlines ongoing research and the potential role for Orca-T in advanced hematologic malignancies.

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

Pumitamig plus chemotherapy generated strong responses across NSCLC subtypes and PD-L1 levels with manageable safety in ROSETTA Lung-02.